Introduction
Mad1 is one of a family of three known bHLHLZip proteins (Ayer et al., 1993) . Mad1 homodimerizes poorly but interacts with Max to form a sequencespeci®c DNA-binding heterodimer. The bHLHLZip domain of Mad1 is required for both heterodimerization with Max and its sequence-speci®c DNA binding (Blackwell et al., 1990) . The Mad1/Max complex binds to the same E box motif as Myc/Max heterodimers but, in contrast to Myc/Max, Mad1/Max complexes function as transcriptional repressors (Amati et al., 1992) through interaction with the co-repressors mSin3A/mSin3B and the mammalian histone acetylases HDAC1 and HDAC2. Mad1 association with mSin3A/ mSin3B/HDAC requires the N-terminal 25 residues of Mad1. Point mutations in this region eliminate not only the interaction between Mad1 and mSin3A/Sin3B/ HDAC but also block Mad1 transcriptional repression . This suggests that Mad1 represses transcription by recruiting histone deacetylases to target sites on DNA (for review: Kiermaier et al., 1997) .
In addition to Mad1, the Mad protein family also comprises Mxi (Zervos et al., 1993) , Mad3 and Mad4 (Hurlin et al., 1995) , all of which speci®cally associate with Max to repress transcription. Mad proteins, like Myc proteins, are short-lived (Ayer et al., 1993) and their expression is tightly regulated during cell cycle progression and in response to induced dierentiation in various cell lines (Ayer et al., 1993; Zervos et al., 1993; Hurlin et al., 1995; Larsson et al., 1994) . In contrast, expression of Max protein is constitutive. However, because both Myc and Mad1 compete for Max (Ayer et al., 1993) , access of Myc to Max is profoundly dependent upon expression of Mad1 (and vice versa) . For this reason, Mad1/Max complexes function as repressors of Myc activity as evidenced by the fact that Mad1/Max (and Mxi/Max) inhibit Myc transactivation of reporter plasmid constructs containing the Myc consensus element (Ayer et al., 1993; Zervos et al., 1993; Backwood et al., 1992) and that Mad1 suppresses Myc transforming activity in rat embryo ®broblasts (Lahoz et al., 1994) . However, it is not clear whether the biological activity of Mad proteins resides solely in their abilities to antagonize Myc proteins or whether, as dominant trans-repressors, they ful®ll other roles. Therefore, to gain further insight into the biological action of Mad1 in vivo, we have generated transgenic mice in which the expression of a Mad1 transgene is targeted to the thymus, a tissue in which both c-Myc and Mad1 are normally expressed (Broussard-Diehl et al., 1996; Foley et al., 1998) . Indeed, in situ hybridization analysis indicates that dierent members of the Mad gene family are expressed in distinct, yet partially overlapping patterns in adult thymus . Since proliferation, dierentiation and apoptosis play such crucial roles during T cell development, the thymus oers itself as a particularly intriguing experimental system in which to examine the consequences of manipulating the Myc/Max/Mad1 network in vivo.
To date, transgenic mouse analysis of the Myc/Max/ Mad1 network has been restricted to ectopic expression of c-myc within the lymphoid compartment (CD2-c-myc, Thy1-c-myc, Em-c-myc) (Stewart et al., 1993; Spanopoulou et al., 1989; Adams et al., 1985) . However, in all such cases deregulated c-myc expression results in the formation of tumors, making it dicult to analyse normal lymphocyte dierentiation in these mice. C-myc knockout mice have also been generated but these die between day E9.5 and E10.5 of gestation (Davis et al., 1993) , before the onset of lymphocyte ontogeny. In contrast, the consequences of ectopic Mad1 expression has not yet been investigated and although Mad1 7/7 have been generated and are viable, no data are available concerning T cell development in these mice.
In this paper, we investigate the eects of expression of a Mad1 transgene under the control of the proximal lck promoter on thymocyte development. We show that although thymus size in lck-Mad1 transgenic mice is drastically reduced, general representation of individual thymocyte sub populations seems overtly normal. We investigated the eects of Mad1 expression on positive thymocyte selection using MHC class I-restricted H-Y-TCR transgenic mice. This analysis shows that Mad1 expression reduces the eciency of positive selection. We also show that thymocytes and splenic T cells from lck-Mad1 transgenic mice display a profound proliferative defect when activated with PMA/Ionomycin or anti-CD3/ CD28 antibody in vitro. Only the ®rst thymocyte G0 -S transition is inhibited by Mad1 expression and this inhibition can be, at least in part, overcome by coexpression of c-Myc.
Results

Generation of lck-Mad1 transgenic mice
To examine the action of Mad1 in vivo, we generated transgenic mice in which a Mad1 transgene was expressed under the control of the T cell lineage speci®c proximal lck promoter which directs expression of the transgene to thymocytes and mature peripheral T lymphocytes (Wildin et al., 1991) . A schematic representation of the transgenic construct is depicted in Figure 1a . Construct DNA was injected into C57BL/ 66CBA F1 embryos using standard techniques . Two founder lines were generated, both harbouring roughly the same copy number (*10 copies, data not shown). Both lines behaved identically and are therefore not further distinguished.
Expression of the Mad1 transgene was monitored by Northern blot analysis using total RNA and a human Mad1 cDNA as a probe. Expression of the transgene was detected in transgenic thymus and spleen tissue. No expression was detected in thymus and spleen from control littermates (Figure 1b) . As a control transgene expression was not detected in heart tissue of transgenic mice.
RT ± PCR analysis performed on RNA derived from sorted thymocyte sub populations such as double negative (DN), double positive (DP) or CD4 + and CD8 + single positive thymocytes (CD8 + SP, CD4 + SP) from lck-Mad1 transgenic mice showed equal expression of the transgene in all thymocyte sub populations ( Figure 1c) . Expression of endogenous Mad1 was detected in the DN, DP and to a weaker extent in the CD4
+ SP sub population ( Figure 1c ). In addition, RT ± PCR analysis on sorted thymocyte sub populations from wild-type and Mad1 transgenic mice showed comparable expression of other Mad family members such as Mxi and Mad4 in dierent thymocyte sub populations (Figure 1c) .
We con®rmed immunohistochemically protein expression of the transgenic Mad1 protein in thymus using a Mad1 speci®c antibody. Staining for the endogenous Mad1 protein was detected with weak intensity. Speci®city of the staining was con®rmed by preincubation of the Mad1 speci®c antibody with its immunogenic peptide which blocked all signal ( Figure  1d ).
Lck-Mad1 transgenic mice exhibit reduced numbers of thymocytes and peripheral T cells but thymocyte sub populations are represented normally Mad1 expression had a dramatic eect on thymic cellularity: thymus size, as well as the total thymocyte number, was reduced by approximately 50% relative to wild-type control littermates (Figure 2a right panel) . To examine the eects of Mad1 expression on T cell development, thymocytes from lck-Mad1 transgenic mice and from control littermates (4 ± 10 weeks old) were analysed by three-color¯ow cytometry using antibodies against CD25, CD44, CD3e, CD69 and TCRa in combination with CD4 and CD8 to discriminate between the dierent thymocyte sub populations. These analyses indicated that Mad1 expression caused no signi®cant change to the ratios of the four thymocyte sub populations in the adult (Figure 2a ). In addition, a more detailed analysis of the four DN sub populations did not reveal a dierence between control littermates and lck-Mad1 transgenic mice (data not shown) indicating no developmental blockade in early T cell development in lck-Mad1 transgenic mice. The level of all cell surface markers tested was unchanged.
To examine any eect that Mad1 expression might have on peripheral T lymphocytes, lymph node cells were analysed by two-color¯ow cytometry using antibodies against CD4 and CD8 to discriminate between the dierent T cell sub populations. These analyses showed a reduction in the percentage of the CD4 + and CD8 + SP population which was accompanied by a reduced number of mature T cells in the peripheral lymph nodes when compared with control littermates (Figure 2b) .
Expression of the lck-Mad1 transgene in an H-Y-TCR background perturbs thymic selection
One way that Mad1 might reduce thymic cellularity is to disrupt positive and/or negative selection. To examine this possibility, we crossed lck-Mad1 transgenic mice with mice expressing a transgenic T cell receptor speci®c for the male H-Y-antigen presented by MHC class I H-2D b . In male mice, the well-established model system for negative selection, almost all thymocytes are negatively selected during T cell development through the interaction of the transgenic H-Y-TCR with the male speci®c H-Y peptide. In female mice, where no male H-Y-antigen is present, selection of MHC class I-restricted CD8 + SP thymocytes proceeds very eciently because thymocytes expressing the H-Y-speci®c transgenic TCR are positively selected (Teh et al., 1989; von Boehmer, 1990 (Figure 3a ). This change in the thymocyte subset distribution was also obvious in the absolute cell number. (Figure 3a + SP thymocytes, a reduction in the mature CD8 + and CD4 + population in the periphery was observed (Figure 3c ). Similar to lck-Mad1 transgenic mice, female lck-Mad1 x H-Y-TCR double transgenic mice showed a decrease in thymic cellularity (table Figure 3a) . Thus, thymic cellularity and thymocyte subset distribution analysis both demonstrate that Mad1 reduces the eciency of positive selection in T cells expressing a class MHC-restricted TCRa/b. + and CD8 + SP thymocytes. Staining of lymph node cells with the same antibodies however showed only a minor reduction in the representation of mature CD8 + cells in the periphery (data not shown). To summarize, we did not observe a signi®cant dierence in total thymocyte number between male lck-Mad16H-Y-TCR double transgenic and male H-Y-TCR mice. In addition, the eect on the percentage of CD8 + cells in the periphery was extremely mild. Thus, the only thing we do conclude from these data is that Mad1 expression does not seem to reduce negative selection.
Impaired mitogen-induced proliferation in lck-Mad1 transgenic mice
In the absence of activation, T cells are arrested in G0. Mitogenic stimulation of the TCR triggers progression into S phase and consequently proliferation. C-myc is well characterized as a gene that is rapidly induced in T cells following mitogenic stimulation (Carding and Reem, 1987) . Moreover, c-myc appears to be necessary for thymocyte proliferation since antisense oligonucleotide inhibition of c-Myc expression blocks S phase entry of T cells (Heikkila et al., 1987) . For this reason, and because of the dramatic eect of Mad1 expression on the total thymocyte cell number in vivo, we next investigated the eect of Mad1 expression on mitogeninduced proliferation.
Thymocytes and puri®ed T cells from lck-Mad1 transgenic mice or control littermates were stimulated with either antiCD3/CD28 antibody or phorbol myristate acetate (PMA) and Ionomycin, and proliferation assayed by [ 3 H]-thymidine incorporation. Mad1 expression signi®cantly suppressed proliferation of both thymocytes and puri®ed splenic T cells in response to either mitogenic stimulus (Figure 4a and data not shown). The eect was not due to changes in the level of TCR, CD3e expression or CD28 expression on the cell surface, which was unaected by Mad1 expression (data not shown). This suppression was not reversed by addition of exogenous recombinant interleukin-2 (IL-2) indicating that the impaired proliferation is not a consequence of impaired autocrine IL-2 stimulation (Figure 4a and data not shown).
p53 is implicated in suppression of cell proliferation in response to a number of stimuli, such as DNA damage, oncogene deregulation (for review Schwartz and Rotter, 1998) and inhibition of CD95/Fas signalling (Zoernig et al., 1998) . Therefore, we were interested to determine whether Mad1-induced growth arrest is dependent upon expression of p53. Lck-Mad1 transgenic mice were crossed with p53 7/7 mice (Donehower et al., 1992) . Thymocytes from p53 +/7 and p53 7/7 non-transgenic and lck-Mad1 transgenic mice were then assayed for their proliferative response to anti-CD3/CD28 mitogenic stimulation. Absence of p53 had no eect on the ability of Mad1 to suppress T lymphocyte proliferation (Figure 4b ).
Mad1-suppression of T lymphocyte proliferation is not accompanied by alterations in described G1 phase cell cycle regulators
Although the Myc/Max/Mad1 network is implicated in the control of cell proliferation (Eilers et al., 1991; Evan et al., 1992; Keath et al., 1984; Heikkila et al., 1987; Roussel et al., 1996) , its precise relationship with the cell cycle machinery remains largely obscure. Progression through the cell cycle is controlled by dierent active cyclin/cdk complexes whose activities are regulated by the availability of regulatory cyclin subunits, the presence of major cdk-inhibitory proteins and by the phosphorylation status of the cyclin/cdk complexes (Albrecht et al., 1998 and ref. therein) . We therefore investigated whether Mad1 expression has any eect on expression or activation of these regulators.
In response to anti-CD3/CD28 stimulation, expression levels of the constitutively expressed cyclindependent kinases cdk2 and cdk4 remain unchanged. In contrast, cyclin E and cyclin D2 are up regulated. Cdk inhibitor p27 is present in quiescent thymocytes but rapidly degraded following mitogen stimulation (Boonen et al., 1999) whereas the Cdk inhibitor p21 is undetectable in quiescent T cells but induced by anti-CD3/CD28 activation (Linette et al., 1996) . As shown in Figure 5a , despite the profound growth-inhibitory eect of Mad1 on thymocytes, the expression patterns of all of these G1 phase cell cycle regulators was unaected (Figure 5a) . Likewise, the immediate early kinetics and extent of expression of c-myc was unaected by growth-inhibitory levels of Mad1 (not shown). In contrast, expression of cyclin A, an indicator of cell proliferation and S phase entry, was markedly suppressed in lck-Mad1 transgenic thymocytes in response to anti-CD3/CD28 stimulation. Expression of cyclin A in unstimulated cells was comparable in wild-type and transgenic thymocytes (Figure 5a ).
In ®broblasts it has been demonstrated that an increased level of cyclin E-dependent kinase activity precedes entry into S phase induced by c-Myc activation (Steiner et al., 1995) and that this is necessary for induction of cyclin A by Myc (Rudolph et al., 1996) . We were curious to see if Mad1 expression in thymocytes would block the induction of cyclin E-dependent kinase activity in response to
anti-CD3/CD28 treatment. Thymocytes from lck-Mad1 transgenic mice and control littermates were stimulated for 48 h with antiCD3/CD28, extracts were prepared from stimulated and unstimulated cells and immune complex kinase assays performed using an anti-cyclin E antibody or control antibody with histone H1 as a substrate ( Figure 5b ). As expected no cyclin Edependent kinase activity was detectable in nonstimulated thymocytes. However, following co-stimulation with antiCD3/CD28, we observed clear increases in cyclin E kinase activity in both wild-type and lckMad1 transgenic mice. Thus, although lck-Mad1 thymocytes exhibit reduced cyclin A levels in response to anti-CD3/CD28 co-stimulation, this was not accompanied by any detectable suppression of cyclin Edependent kinase activity.
Expression of Mad1 in T cells blocks only the first G0-S entry into the cell cycle but not subsequent cell cycles
Initial entry of quiescent T cells from G0 into the cell cycle appears to be a mechanistically discrete process from the M-G1 transition of continuously proliferating cells. Unlike exit from M phase, exit from G0 is accompanied by transient expression of immediate early genes and the G0-S transition takes far longer than the equivalent transition from M to S phase. It is still unclear whether the Myc/Max/Mad1 network is primarily concerned with the G0-G1 transition or whether it ful®ls a reoccurring or sustained role in continuously proliferating cells. For this reason, we decided to investigate whether the growth-inhibitory eect of Mad1 was exerted only at the exit from quiescence or also in each reoccurring cell cycle.
To monitor proliferation over time in response to anti-CD3/CD28 stimulation puri®ed T cells from lckMad1 transgenic mice or control littermates were labelled in vitro for 72 h using the¯uorescent dye CFSE (Wells et al., 1997) . This dye binds irreversibly to the cell surface and segregates equally between daughter cells upon cell division. As cells divide their uorescence halves sequentially with each generation. When analysed by¯ow cytometry, gating on the living cells showed that unstimulated splenic T cells from either lck-Mad1 transgenic mice or control littermates exhibited a sharp single peak indicative of no cell (Figure 6a, left panel) . In contrast, activation of T cells from control littermates resulted in the appearance of several distinct peaks representing successive cell divisions. We observed marked heterogeneity and asynchrony in the kinetics of cell division, with some cells having divided as many as ®ve times after 72 h of co-stimulation (peak 6) whilst others remained undivided (peak 1). T cells from lck-Mad1 transgenic mice consistently exhibited fewer cell divisions in response to anti-CD3/CD28 treatment, as evidenced by reduced peak sizes and a smaller percentages of divided cells. 19.0% of the alive T cells remained undivided in the control T cell population, whereas 36.9% of the alive T cells of lck-Mad1 transgenic T cells remained undivided (Figure 6a , left panel and table). This indicates that the initial G0-G1 entry into the cell cycle is clearly inhibited by Mad1 transgene expression. To investigate the eects of Mad1 expression on cells already in cycle, splenic T cells that had already divided three times (peak 4) were sorted and re-plated for 24 h in the presence of IL-2 on anti-CD3/CD28 coated plates. The CFSE pro®les from both lck-Mad1 transgenic mice and control littermates were then compared. We observed negligible dierences between CFSE pro®les of control and lck-Mad1 thymocytes (Figure 6b ), indicating that Mad1 exerts no antiproliferative in¯uence over cells already past the G0-G1 boundary. This conclusion was con®rmed by CFSE staining combined with Hoechst 33343 staining. Anti-CD3/CD28 activated, CFSE-stained splenic T cells were incubated with the intercalating dye Hoechst 33343 and analysed by¯ow cytometry. Both CFSEand cell cycle pro®les were obtained. By gating on dierent peaks in the CFSE pro®le, the corresponding Hoechst cell cycle pro®les were then identi®ed. The cell cycle distribution of the nondivided population of CFSE stained T cells (peak 1) revealed a slightly increased number of T cells in G1 and a reduced number of T cells in S phase in lck-Mad1 transgenic mice compared to wild-type littermates. Analysing the cell cycle distribution of cycling cells by gating on a population of already divided T cells (peak 2) showed no dierence in the cell cycle pro®le between wild-type and lck-Mad1 transgenic mice supporting the notion that Mad1 inhibits only the entry in the ®rst cycle and does not aect normal cell cycle progression of already cycling T cells (Figure 6c ).
c-Myc can overcome the proliferation block caused by Mad1 expression
The general model of the Myc/Max/Mad1 network holds that proteins of the Mad family compete with Myc for Max and that Mad/Max heterodimers compete with Myc/Max heterodimers for binding to DNA. However, neither relative anities of Myc and Mad proteins for Max and DNA, nor the precise stoichiometries of Myc and Mad proteins in normal cells have been well de®ned. However, it is known that normal cells express very low levels of c-Myc protein and that levels of c-Myc in tumor cells can be up to 100 times higher (Moore et al., 1998) . To test in vivo the notion that Myc and Mad1 compete functionally, we crossed our lck-Mad1 transgenic mice with mice expressing the 4-hydroxytamoxifen (4-OHT)-dependent c-MycER TM protein under the control of the proximal lck promoter. Both lck-Mad1 and lck-c-mycER TM transgenic mice possess similar copy numbers of their requisite transgene (data not shown and Rudolph et al., 2000) .
Lck-c-mycER TM /lck-Mad1 double transgenic mice as well as single transgenic and control littermates were injected with 4-hydroxytamoxifen (4-OHT) to activate (Mad1), either before (NS) or after treatment with immobilized anti-CD3/CD28 (CD3/CD28) for 48 h. Cyclin E-dependent kinase activity in wild-type and in Mad1 transgenic thymocytes was assessed by immune complex kinase assay using either an anticyclin E serum (cyc E) or a control antibody (co) with histone H1 as a substrate
Analysis of Mad1 function in T cells using lck-Mad1 transgenic mice B Rudolph et al c-MycER TM in vivo. After 9 ± 12 days of daily 4-OHT administration, mice were analysed for proliferation in response to anti-CD3/CD28 activation. Puri®ed T cells from double transgenic lck-c-mycER TM /lck-Mad1 mice and their control littermates were CFSE stained and stimulated with anti-CD3/CD28 for 72 h. When analysed by¯ow cytometry, the stimulated T cells from lck-c-mycER TM transgenic mice (Figure 7b ) exhibited increased proliferation relative to cells from a wild-type control littermate (Figure 7a ). The phenotype of the lck-c-mycER TM transgenic mice is therefore opposite to that shown by lck-Mad1 transgenic mice which show less proliferation compared to a wild-type control after anti-CD3/CD28 activation (Figures 4 and 6) . In contrast to single transgenic mice, T cells from lck-c-mycER TM /lck-Mad1 double transgenic mice injected with 4-OHT showed a proliferation pro®le similar to that of lck-c-mycER TM transgenic mice (Figure 7c ), indicating that activation of c-myc in vivo can overcome the suppression of proliferation caused by Mad1 expression. The eect was absolutely dependent on the presence of 4-OHT since T cells from double transgenic mice in which cmyc was not activated (oil injection) showed a proliferation pro®le identical to that of lck-Mad1 transgenic littermates (Figure 7d) . Thus, we conclude that Myc and Mad1 compete on the same pathway though we cannot exclude the possiblity that Myc simply acts downstream of Mad1 in a completely independent way. 6 CFSE stained, puri®ed and anti-CD3/ CD28-activated T cells from control littermates (wt) and lck-Mad1 transgenic mice (Mad1) were stained with Hoechst 33342 followed by¯ow cytometric analysis. A gate was set using the CFSE pro®le shown in (a) on non-divided T cells (peak 1) and on T cells that have divided once (peak 2). The corresponding Hoechst 33342 cell cycle pro®les were analysed. Flow cytometric pro®les from undivided T cells (c left) and pro®les from T cells that have divided once (c right) are shown. One representative experiment out of three experiments is shown
Discussion
Mad1 is a sequence-speci®c DNA binding bHLHZip protein identi®ed through interaction with Max, the common partner in the Myc/Max/Mad1 network (Ayer et al., 1993) . The notion that Mad proteins antagonize functionally the activities of the Myc protein family (Ayer et al., 1993; Hurlin et al., 1995; Amati et al., 1994 ) is based upon three in vitro observations. First, the ability of Mad1 to compete with Myc for binding to its partner protein Max; second, the ability of Mad1/Max heterodimers to compete with Myc/Max heterodimers for sequencespeci®c DNA binding sites and third the opposing transcriptional activities of Mad1 and Myc as repressor and activator, respectively. If these in vitro data hold true in vivo, we would presume that transgenic expression of lck-Mad1 would antagonize the function of endogenous c-myc (Ayer et al., 1992; Amati et al., 1993) . However, there is as yet no evidence that Mad1 can suppress Myc action in vivo. Moreover, it is possible that Mad proteins, which are potent transcriptional repressors, exert other functions in addition to antagonizing Myc.
We therefore decided to examine the eects of perturbing the Myc/Max/Mad1 network in vivo by transgenic expression of Mad1 in thymus and peripheral T cells ± tissues in which ontogeny, proliferation, dierentiation and apoptosis, all important attributes of the Myc/Max/Mad1 network, play important parts. In fact, one existing study has examined the eect of transgenic expression of Max under control of the immunoglobulin heavy chain enchancer (E) in T cells and shown that Max attenuates Myc-induced lymphoproliferation and lymphomagenesis in Myc/Max double transgenic mice (Lindemann et al., 1995) . However, because Max is the central shared component within the Myc/Max/Mad1 network, it has the capability of enhancing not only Myc but also Mad1 activity, making interpretation of this study dicult.
We chose to examine the eect of ectopic expression of the Mad1 protein in vivo by generating transgenic mice expressing Mad1 under the control of the T cell speci®c proximal lck promoter. Perhaps surprisingly, these mice display apparently normal T cell development with no signi®cant eect on the representation of various thymocyte sub populations. This is similar to the ®ndings of a recent study in which Max was transgenically expressed in B cells under the control of the immunoglobulin Em heavy chain enchancer. The distribution of dierent T cell sub populations appeared normal in Em-Max mice (Lindemann et al., 1995) . The observed robust homeostasis of T lymphocyte development, even in the face of major experimental genetic manipulation, is well acknowledged even though its basis remains a mystery.
To analyse the eect of lck-Mad1 expression on T cell development in detail, we used the H-Y-TCR model for T cell selection (von Boehmer, 1990 ). Our analysis indicates that deregulated Mad1 expression exerts eects on positive thymocyte selection reducing the eciency of the generation of CD8 + SP. One obvious feature of the lck-Mad1-transgenic mice was a marked reduction in lymphoid cellularity, accompanied by an impaired T cell proliferation in response to anti-CD3/CD28 or PMA/Ionomycin treatment in vitro. This raises the possibility that the reduced in vivo lymphoid cellularity induced by Mad1 expression arises by inhibition of proliferation during the early phase of thymocyte proliferation. The block in proliferation observed in lck-Mad1 thymocytes and T cells in vitro is consistent with a recently published report showing increased proliferation of mxi 7/7 T cells in response to anti-CD3/CD28 treatment (SchreiberAgus et al., 1998) , matched by an increase in the percentage of mxi 7/7 splenic T cells exiting from G1 phase.
As might be expected from the broad pattern of expression of Myc and Mad proteins, the suppressive eect of Mad1 expression on proliferation does not appear to be cell type speci®c. Ectopic expression of Mad1 inhibits NIH3T3 cell line proliferation in response to activation of the CSF-1 receptor, leading to a signi®cant increase of the fraction of G1 phase cells (Roussel et al., 1996) , whereas cell cycle exit of granulocytic precursors from Mad 7/7 mice is inhibited relative to control cells (Foley et al., 1998) . Notably, the growth-inhibitory eect of Mad1 we observe on What might be the mechanism by which Mad1 expression suppresses thymocyte proliferation? Initiation of T lymphocyte proliferation involves activation of the T cell receptor (TCR) and the CD28 co-receptor by antigens or activating antibodies which initiates an intracellular cascade of signalling events culminating in activation of critical genes such as c-myc and IL-2 that are required for T cell proliferation. Autocrine stimulation by IL-2 is absolutely required for T cell proliferation, raising the possibility that one eect of Mad1 expression might be the inhibition of IL-2 synthesis or secretion. However, this does not seem to be the case since addition of recombinant IL-2 to anti-CD3/CD28 stimulated lck-Mad1 transgenic thymocytes and splenic T cells failed to restore proliferation to normal levels. A similar observation has also been made in mice expressing IkBa or FADD DN under the control of the proximal lck promoter (Boothby et al., 1997; Zoernig et al., 1998) , both of which also show a profound block in T cell proliferation.
To investigate further the mechanism underlying the block of T cell proliferation in lck-Mad1 transgenic mice, we analysed the behaviour of a number of key molecules implicated in G1 phase cell cycle progression. Activation of Myc in arrested RAT1A-MycER ®broblasts stimulates expression of both cyclin E and cyclin A (Janser-Duerr et al., 1993) and S phase entry is preceded by increased levels of cyclin E-dependent kinase activity (Steiner et al., 1995) . However, in thymocytes from our lck-Mad1 transgenic mice, kinetics and levels of expression of G1 phase cdks, cyclins and the cdk inhibitors p21 and p27 in response to anti-CD3/CD28 treatment all appeared identical to that of control thymocytes. Only cyclin A, a typical S phase cyclin, appeared to be altered in lck-Mad1 thymocytes, consistent with a block in cell cycle progression at the transition from G1 into S phase. These data support the notion that Mad proteins function to regulate cell growth by regulating the exit from G1 phase (Roussel et al., 1996; Foley et al., 1998) .
We next investigated whether Mad1-induced growth arrest might be p53-dependent. However, loss of p53 had no eect on the ability of Mad to suppress T cell proliferation. Consistent with this observation, p53 also did not seem to be required for Myc-induced proliferation. Consistently, ectopic expression of cmyc induces proliferation in p53 7/7 MEFs (Hermeking and Eick, 1994; Wagner et al., 1994) . The relationship between proteins of the Myc/Max/Mad1 network and p53 is unclear. However, p53 has been implicated in mediating Myc-induced apoptosis (Hsu et al., 1995) , although this probably re¯ects synergy between the two rather than a dependence of one on the other (Juin et al., 1999) . Nonetheless, mice transgenically expressing c-myc on a p53 negative background show accelerated development of malignant lymphomas (Hsu et al., 1995; Elson et al., 1995) .
The notion that Mad1 can act as a p53-independent tumor suppressor is an intriguing one that has never been tested directly. However, there are observations that support the idea. First, Mad1 suppresses c-mycinduced transformation in rat embryo ®broblasts (Lahoz et al., 1994) . Second, mad1 maps to a chromosomal region altered in certain human tumors (Edelho, 1994) . Third, an adenovirus vector encoding Mad1 dramatically inhibits the tumorigenicity of human astrocytoma cells in nude mice (Chen et al., 1995) . Thus, manipulation of Mad family members may be an eective way of suppressing cell growth even in tumors lacking functional p53.
Materials and methods
Generation of transgenic mice
A cDNA encoding human Mad1 (Ayer et al., 1993) was cloned into the BamHI cloning site of the transgenic expression vector p1070 (Chan et al., 1990) . The lckMad1 transgene was microinjected into the male pronucleus of fertilised C57BL/6/CBA F1 embryos. Injected embryos were transferred into pseudo-pregnant foster mice. Transgenic founders were detected by Southern blot analysis using a human growth hormone (hgh) probe to detect the transgenic construct. Two independent Mad1 transgenic lines were established.
The generation of lck-c-mycER TM transgenic mice is described elsewhere (Rudolph et al., 2000) . H-Y-TCR transgenic mice (H-2 b/b ) were originally described by von Boehmer (1990) . Osprings from lck-Mad16H-Y-TCR crosses were analysed. The status of the MHC locus was assessed by Southern blot analysis using an H-Y-TCR probe (Bluthmann et al., 1988) . Mice with H-2 b/k status were analysed. P53 7/7 mice were originally described by Donehower et al. (1992) .
In vivo activation of lck-c-mycER TM transgene
In vivo activation of lck-c-mycER TM transgene was performed as described by Rudolph et al. (2000) .
RNA expression analysis
Total RNA from thymus and spleen was isolated using Trizol reagent (Gibco ± BRL). Northern blot analysis was performed using standard techniques (Sambrook et al., 1989) . The membrane was probed with a human Mad1 cDNA (Ayer et al., 1993) .
For RT ± PCR analysis, total RNA from sorted thymocyte sub populations was prepared using Trizol reagent (Gibco ± BRL). RNA was DNAse I (Boehringer Mannheim) treated and cDNA was synthesized using random hexamer primer and Superscript TM RNaseH 7 Reverse Transcriptase (Gibco ± BRL). RT ± PCR expression analysis was performed using primers speci®c for Mad1, Mxi, Mad4 and bactin. (Mad1: 5'-CTCTGATAGAGAAGAACTGGACG-3', 5'-TCGTCCGA-GTCACTCACGCTG-3', Mxi: 5'-ACACTTTTCTGCAGAA-CGTGC-3', 5'-TGAGGCGTAGCCATGTTCACA-3', Mad4: 5'-ACAGGTCTTCACACAACGAAC-3', 5'-CTCAGAGTA-GTGTGACGTG-3'). Radiolabelled ampli®cation products were visualized by autoradiography.
For non-radioactive detection of Mad1 expression in anti-CD3/CD28 stimulated, sorted puri®ed T cells the following primer pair was used: 5'-CGGGCTCATCTTCGCTTG-3', 5'-ACGGTGGAGCGGATGCGTC-3'.
Immunohistochemical staining
For histological examination, thymus tissue was snap frozen and 5 mm sections were prepared. Mad1 protein expression was detected using a Mad1 speci®c antibody (Santa Cruz Biotechnology).
Cell surface staining and flow cytometry
Flow cytometry analysis was performed as described by Rudolph et al. (2000) .
Western immunoblot analysis
Tissues were lysed in 125 mM Tris-HCl, pH 8.0, 2 mM EDTA, pH 8.0, 2.5% SDS and 10% b-mercaptoethanol. 20 mg protein lysate/sample was used for Western immunoblot with the following antibodies: cyclin E, cdk 2, cdk 4, cyclin A (Santa Cruz Biotechnology), cyclin D2 and D3 (kind gifts of Dr Peter Parker, ICRF).
Immunoprecipitations and immune complex kinase assays
Cyclin E immunoprecipitations and cyclin E-dependent kinase assays were performed according to Dulic et al. (1994) using the anti-cyclin E (M20) antibody (Santa Cruz Biotechnology).
Purification of splenic T cells
Puri®cation of splenic T cells was performed using mouse T cell Enrichment Columns (R&D systems).
In vitro proliferation assay
1610
5 thymocytes or puri®ed splenic T cells/96-well were cultured in DMEM medium (Gibco ± BRL) supplemented with 10% FCS, 50 mM 2-mercaptoethanol, 1 mM sodium pyruvate, 100 u/ml penicillin, 100 mg/ml streptomycin in the presence of plate-bound anti-CD3/CD28 antibody (PharMingen: 10 mg/ml each) or PMA/Ionomycin (PMA: Sigma 2 ng/ ml, Ionomycin: Calbiochem 0.2 mg/ml). In the case of thymocytes derived from lck-c-mycER TM /Mad1 double transgenic mice or their control littermates, 200 nM 4-hydroxytamoxifen (RBI) was added to the medium. To determine IL-2 dependence of the proliferation, recombinant IL-2 (Chiron UK: 20 ng/ml) was added to the culture medium. At various time points, proliferation was assessed by adding 
CFSE and Hoechst 33342 staining
Puri®ed splenic T cells were stained with the¯uorescent dye carboxy¯uorescein succinimidyl ester (CFSE, Molecular Probes) (Wells et al., 1997; Lyons and Parish, 1994) . Brie¯y, puri®ed splenic T cells were resuspended at a density of maximal 1610 7 cells per ml in 0.1% BSA/PBS. CFSE was added to a ®nal concentration of 10 mM and cells were incubated at 378C for 10 min.
For lymphocyte activation studies, CFSE labelled splenic T cells were plated on 24-well plates in the presence of immobilised anti-CD3/CD28 antibody (PharMingen: 10 mg/ ml each). Seventy-two hours after T cell activation CFSE labelled splenic T cells were analysed by¯ow cytometry. A control of CFSE-stained T cells incubated for the same time without activation aided identi®cation of the population of cells in the CFSE pro®le that had not divided.
For cell sorting, CFSE stained, activated T cells were resuspended in PBS containing 2% FCS, soluble antiCD3/ CD28 antibody (2 mg/ml) and recombinant IL-2 (Chiron UK: 20 ng/ml). After sorting, 1610 5 T cells were replated for 24 h in the presence of plate-bound anti-CD3/CD28 antibody (PharMingen: 10 mg/ml each) and recombinant IL-2. CFSE pro®les were analysed by¯ow cytometry. To obtain a Hoechst 33342 cell cycle pro®le in parallel with the CFSE staining, activated, CFSE stained T cells were collected by centrifugation and treated with Hoechst 33342 (Hoechst; 10 mg/ml) for 30 min at 378C. To distinguish live from dead cells, propidium iodide (5 mg/ml) was added before FACS analysis. CFSE/Hoechst pro®les were analysed using a FACSvantage dual laser¯ow cytometer (Becton Dickinson).
